Astellas Pharma has entered into a partnership with Roche Diabetes Care Japan to develop and commercialise Roche Diabetes Care’s Accu-Chek Guide Me blood glucose monitoring system, as a combined medical product with BlueStar.
Developed by Welldoc, BlueStar is a digital health solution for diabetes patients, the product is currently available in the U.S and Canada. Welldoc and Astellas are jointly developing BlueStar in Japan.
The combined medical product will support patients to manage their diabetes by utilising Accu-Chek Guide Me to obtain blood glucose data, as well as tracking diet, exercise, activity and medication through Welldoc BlueStar app. A unique artificial intelligence (AI)-algorithm and personalised coaching messages are intended to support patients to build better habits over time.
"Together with Astellas, Roche Diabetes Care is making innovations in diabetes care more accessible through connected devices and digital products, to bring true relief for people living with diabetes," said Noriko Hattori, Country Manager of Roche Diabetes Care Japan. "We are creating patient-centered value by enabling access to relevant data insights for informed diabetes therapy management, facilitating clinical development and regulatory and reimbursement decisions."
Click here to read the original news story